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Abstract
Background: Whereas ultra-short stay (day care or 24 hour hospitalisation) following breast
cancer surgery was introduced in the US and Canada in the 1990s, it is not yet common practice
in Europe. This paper describes the design of the MaDO study, which involves the implementation
of ultra short stay admission for patients after breast cancer surgery, and evaluates whether the
targets of the implementation strategy are reached. The ultra short stay programme and the
applied implementation strategy will be evaluated from the economic perspective.
Methods/design: The MaDO study is a pre-post-controlled multi-centre study, that is performed
in four hospitals in the Netherlands. It includes a pre and post measuring period of six months each
with six months of implementation in between in at least 40 patients per hospital per measurement
period.
Primary outcome measure is the percentage of patients treated in ultra short stay. Secondary
endpoints are the percentage of patients treated according to protocol, degree of involvement of
home care nursing, quality of care from the patient's perspective, cost-effectiveness of the ultra
short stay programme and cost-effectiveness of the implementation strategy. Quality of care will
be measured by the QUOTE-breast cancer instrument, cost-effectiveness of the ultra short stay
programme will be measured by means of the EuroQol (administered at four time-points) and a
cost book for patients. Cost-effectiveness analysis will be performed from a societal perspective.
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Cost-effectiveness of the implementation strategy will be measured by determination of the costs
of implementation activities.
Discussion: This study will reveal barriers and facilitators for implementation of the ultra short
stay programme. Moreover, the results of the study will provide information about the cost-
effectiveness of the ultra short stay programme and the implementation strategy.
Trial registration: Current Controlled Trials ISRCTN77253391.
Background
Opinions on more optimal working methods ('best prac-
tice') for breast cancer treatment have been changing con-
tinuously[1-6]. Increasingly, implementation studies are
applied investigating techniques how to change clinical
practice to integrate 'best practice' recommendations[7,8].
Whether a new programme is consolidated after imple-
mentation depends on the quality of care, the cost-effec-
tiveness of the innovation as such, and of the cost-
effectiveness of the innovation incorporating the costs of
implementation[9].
Breast cancer causes a prominent burden on the health
care budget. Of the total costs of breast cancer treatment
35–50%[10] is spent on surgical treatment, of which the
largest part is on account of the hospital stay. Since the
1990s, hospital stay has decreased from 10–14 days to 5–
7 days and further to the level of day care admission[11-
15]. Three randomised clinical trials on the subject of
early discharge (2–4 days vs. 5–10 days) reported no
adverse effects and lower illness rates, high patient satis-
faction and good clinical outcomes for the early discharge
as compared to the standard admission group[16-18].
A decrease in admission time should not affect quality of
care in a negative way. Therefore, it is important to intro-
duce a structured programme such as has been developed
at University Hospital Maastricht (uhM) that includes cur-
rent quality of care criteria[4,5,19]. Moreover, criteria for
education, support and evaluation of the breast cancer
care programme can (provide information to) enhance
quality of care. Measurement of quality of care is of fun-
damental importance when evaluating a new programme.
At the uhM, an ultra short stay programme for breast can-
cer surgery was developed and evaluated, incorporating
the aspects mentioned above. The programme consists of
a structured care organisation including education and
counselling, dedicated anaesthesia, active participation of
the patient in her own treatment plan and in the decision
to go home, and home care nursing. NABON guideline
quality indicators are also incorporated in the programme
(e.g. access time for the first visit to the Breast Unit, time
spent in the process, number of breast conserving proce-
dures and all diagnostic and treatment decisions being
made in an appropriate multidisciplinary setting)[19].
Although the uhM programme was successful in the end,
the programme was greeted with scepticism by both
health care providers and members of the local breast can-
cer patient association. For example, in the beginning
patients were discouraged by ward nurses to go home in
the evening following surgery for the nurses did not trust
the quality of the programme at that moment. In addi-
tion, it suffered from problems at the anaesthesiology
department (e.g. administration of opioids at the recovery
unit postoperatively even if patients did not suffer pain)
and from organisational flaws. For instance, the day care
surgery unit closed at 1800 hours and, therefore, patients
operated on late in the afternoon had less recovery time as
compared to those operated on early in the morning. Fol-
lowing on those limited opening hours, patients in need
of more time to recover after 1800 hours were transferred
to the inpatient ward from which discharge the same
evening was rarely performed.
Traditionally, implementation strategies have been cho-
sen for pragmatic reasons guided by personal acquaint-
ance with a particular strategy[20]. In this project we
chose to perform an extensive diagnostic analysis[20] of
the problem, consisting of three issues:
1) how is current care organised?
2) how does it deviate from optimal care according to the
innovative care programme?
3) what are barriers and facilitators for implementation of
the ultra short stay programme?
The uhM experience accumulated valuable insight and
knowledge about implementation of an ultra short stay
programme for breast cancer. If such a programme is
implemented on a wider scale, in other hospitals, these
experiences may contribute to the design of implementa-
tion strategies that are tailored to local needs.
The implementation strategy will be developed on the
basis of the results of the diagnostic problem analyses,
and tailored to the needs of the stakeholder groups. The
insights generated from this study may be translated intoBMC Cancer 2007, 7:117 http://www.biomedcentral.com/1471-2407/7/117
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generally applicable insights on implementation of the
innovative care programme on a larger scale while again
defining patient benefits and demonstrating cost contain-
ment through the type of care provided.
Aim and objectives
Aim
The aim of this study is to implement a programme incor-
porating breast cancer surgery in an ambulatory/24 hour
stay setting, (tailored to the needs of these hospitals).
Objectives
To evaluate:
1) whether the percentage of patients treated in ultra short
stay increases without an increase in the number of com-
plications.
2) whether the quality of care as perceived by patients
between the baseline measurement and measurement
after implementation does not deteriorate.
3) the cost-effectiveness of the ultra short stay programme
versus care as usual (programme cost-effectiveness) in the
baseline period.
4) the cost-effectiveness of implementation of the ultra
short stay programme versus 'doing nothing' (policy cost-
effectiveness).
5) the actual performance of the professionals in the test
hospitals according to performance indicators.
6) the perceived barriers and facilitators for the imple-
mentation of the programme incorporating surgery in
ambulatory/24 hour stay setting in the participating hos-
pitals so others preparing to change to ultra short stay care
can profit from this information.
Methods/Design
Study design
The MaDO study is a multi-centre pre-post uncontrolled
prospective study and involves breast cancer patients who
are operated on with curative intent. Both pre and post-
measurements last six months with an implementation
period of six months in between.
Selection of hospitals
The study is performed in four hospitals which have been
selected on three criteria. First, all participating hospitals
had to be recognised as early adopters (an active group
with high status within the target group)[21] within the
field of breast cancer treatment, expressed by the willing-
ness to appoint a full-time breast nurse. Second, we
wished to include one university hospital, one large train-
ing hospital, one small training hospital and one non-
training hospital to cover the main organisational hospi-
tal settings in the Netherlands, and to assess whether dif-
ference in results could be explained by differences in
setting. Third, recruitment of people from different hospi-
tals from different parts in the Netherlands, enables us to
have a representative sample of breast cancer patients in
the Netherlands
Selection of patients
Inclusion criteria
All consecutive patients from the four participating hospi-
tals, aged over 17 years, diagnosed with breast cancer, and
scheduled to undergo surgery are eligible for participation
in the study.
Exclusion criteria
Concerning surgical techniques, there is no contra-indica-
tion for ultra-short stay. Patients whose physiology
impedes participation, as assessed by the breast surgeon
and breast nurse, are excluded from the study. Patients
who cannot rely on sufficient informal care in the home
situation during the first night following surgery and
patients with complaints that necessitate postoperative
monitoring (e.g. cardial, pulmonal or neurological dis-
eases) are scheduled for at least one overnight stay. This
decision is made in consultation with the anaesthesiolo-
gist. The breast nurse scores the reasons for patients who
do not participate.
Informed consent
Eligible patients are informed about the study by the
breast nurse during a consultation separate from the con-
sultation in which they are informed about the diagnosis
breast cancer. Patients are given an informed consent
form by the breast nurse when they are informed about
the study, and they are asked to return the signed
informed consent within a week. The informed consent
regards consent to being asked to complete question-
naires with the aim to evaluate the cost-effectiveness of
(the implementation of) the innovative care programme.
Sample size calculations
In the uhM the percentage of patients discharged within
24 hours has increased from 13% to 84%. Our assump-
tion is that the clinically significant difference of ultra
short stay admissions between the pre and post measure-
ment is at least 30% in all participating hospitals. To
achieve this percentage, 40 patients are sufficient for both
the pre and the post measurement in each of the hospitals
to demonstrate statistical relevance (p < 0.05) with a
power of 0.90[22].BMC Cancer 2007, 7:117 http://www.biomedcentral.com/1471-2407/7/117
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Intervention: the breast cancer care programme including 
ultra short stay
The intervention in this study concerns the comprehen-
sive care programme for breast cancer surgery in ultra
short stay (= ambulatory/24 hours stay setting). The key
figures in the programme are the multidisciplinary team,
the breast nurse, and the patient.
Traditionally, the surgeon has been the specialist who
analyses the type of breast pathology presented. Preven-
tive procedures, early diagnosis of non-palpable lesions,
breast conserving therapy, and lymph node sparing ther-
apy have raised possibilities to reduce the burden of breast
(cancer) surgery. The role of the breast nurse was intro-
duced to improve patient counselling. Through these
developments, diagnosis and treatment of breast pathol-
ogy have gained a more multidisciplinary character. A
decrease in the burden of surgery may limit the need for
hospital-based supportive care. Similarly, this leads to a
demand for strict coordination of the different steps and
disciplines involved. Moreover, responsibilities for
aspects of care need to be reallocated to other persons:
from hospital- based supportive caregiver towards infor-
mal caregiver, from clinician to nurse specialist, from in
house nursing staff to outpatient nursing staff, from hos-
pital-based nursing staff to home care nursing staff etc.
While the clinician's activities are limited to solving med-
ical problems, the breast nurse performs all coordinating
tasks to create a programme that runs smoothly.
The patient is the key figure in the process. In a one-hour
consultation, following the preoperative diagnosis, the
patient is informed by the breast nurse about all aspects of
surgery (preparation, day of surgery, medication etc.). A
checklist is used for this consultation and all oral informa-
tion is supported by written information. Parts of this
information (e.g. information on home care nursing and
what to do in case of problems) are repeated on the morn-
ing of surgery, and at the moment of discharge.
Implementation strategy
The first step in the implementation process concerns the
assessment of the guideline recommendations by consen-
sus among experts, who define the complete set of recom-
mendations (n = 29) as well as a set of key
recommendations (Table 1).
A so-called diagnostic analysis assesses the usual care, and
explores factors that impede or facilitate the bridging of
the gap between usual care and the programme to be
implemented. Information for the diagnostics analysis
will be retrieved from interviews during outreach visits,
meetings, and telephone and e-mail conferences. The
results of the assessment of usual care in the participating
hospitals are compared to the standards of the innovative
care programme. Information on perceived barriers and
facilitators for implementation of the ultra short stay pro-
gramme will be collected during outreach visits to the hos-
pitals. These visits will be conducted in the recruitment
and preparation phase. They will be aimed at preparation
of the actual implementation and listing of the barriers
and facilitators that were perceived by the participants for
implementation of the care programme. This set of barri-
ers and facilitators will be described on different levels:
study guideline, care provider, patient, colleague, organi-
sation, and financial resources and reimbursement[23].
Subsequently, a hospital-specific strategy is applied to
implement a hospital-tailored version of the comprehen-
sive care programme. This strategy is aimed at overcoming
the barriers. Multi-faceted implementation strategies are
used, providing insight, inducing change and acceptance,
and feedback to maintain changes. These strategies are
based on several components: 1) The promise that each
early adopter makes to the project leader (MvM) to
appoint a breast nurse fully available for coordination for
the programme; 2) High-frequency outreach visits and
study group meetings representing all disciplines involved
in breast cancer care, provide the forum in which all steps
for implementation are prepared, and issues are discussed
and resolved. This local working party is also responsible
for the communication of progress of implementation
and of the findings within the hospital, to patients, and to
other involved parties.; 3) The care process is measured
through indicators mentioned in the Case Record Forms
that are scored within the hospital, followed by feedback
on performance by the researchers.
Main indicators (Table 2)
Measurements and timing of measurements (Figure 1)
- Information on the achievement of the targets of the
implementation strategy is collected through Case Record
Forms.
- Quality of care is measured from the patient's perspective
through the QUOTE-breast cancer, a questionnaire that
was developed by and for breast cancer patients and con-
cerns those aspects that breast cancer patients perceive as
most important when assessing quality of care[24,25].
The QUOTE-breast cancer questionnaire is filled out six
weeks after surgery.
- Information on the performance of professionals is
gained through Case Record Forms. The performance
indicators have been developed by means of a consensus
procedure in the uhM project group.
- Information on societal costs are retrieved from hospital
information systems and through a prospective cost bookBMC Cancer 2007, 7:117 http://www.biomedcentral.com/1471-2407/7/117
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that is filled out by patients during six weeks from the
moment of discharge. The day before surgery, patients are
asked to fill out a retrospective cost book to assess the
patients' health-care related costs for a period of two
weeks prior to surgery.
- Patients fill out EuroQol questionnaires at baseline (one
day before surgery) and at 24 hours, one week and six
weeks after surgery.
When patients sign informed consent and receive the
questionnaires, a stamped envelope is given to them
which can be used to return the set of questionnaires.
Programme cost-effectiveness (as compared to care as
usual) consists of the two components costs and effective-
ness, and is expressed as incremental costs per Quality
Adjusted Life Year (QALY) of the ultra short stay pro-
gramme versus care as usual. Incremental costs are
expressed as the difference in costs between the ultra short
stay programme and care as usual. Costs are calculated by
multiplying the volumes with the appropriate cost prices.
Information on (societal) costs are retrieved from hospital
information systems and through a prospective cost book
that is filled out by patients during six weeks from the
moment of discharge. Effectiveness of the programme is
determined through the measurement of safety, (number
of complications, number of visits to the emergency unit,
number of re-admissions etc.; information gained from
the Case Record Forms) and generic health-related Qual-
ity of Life. Generic health-related Quality of Life is
recorded through the EuroQol-5D (EQ-5D)[26], which is
completed at baseline, 24-hours after surgery, 1 week after
surgery and 6 weeks after surgery. QALYs will be deter-
mined in two ways; from a societal perspective using the
Dolan score, and from an individual perspective using the
VAS score of the EuroQol. The multiple imputation
method will be used for missing data analysis[27].
- Policy cost-effectiveness of implementation of the ultra
short stay programme versus 'doing nothing' is expressed
as incremental costs per Quality Adjusted Life Year
(QALY). Costs of the implementation strategy is meas-
ured through cost forms that participants in the study
Table 1: Key recommendations of the study guideline to enable ultra short stay for breast cancer surgery. The complete guideline 
contains 29 recommendations. The participating breast nurses and surgeons from the study groups rated all recommendations and 
decided upon which recommendations would be defined as 'key' recommendations.
• The treatment of all breast cancer patients is planned in a weekly multidisciplinary meeting.
• The interval between referral and first visit to the breast unit is 5 working days or less.
• The interval between diagnostic tests and informing patients about their results is 5 working days or less.
• The interval between the decision to operate and surgery is 15 working days or less.
• The number of preoperative hospital visits is minimised.
• The general practitioner is informed about diagnosis, treatment plan and potential side-effects prior to surgery.
• Patients planned for day care treatment are postoperatively given the choice between continuation of admission and discharge.
• Information given to patients about discharge is supported by written information.
• Decisions on patient discharge are based on clear guidelines.
• Specialised home care* for patients in the period following surgery is facilitated.
• The breast nurse stays in contact with the patient during the postoperative period.
• At least one night of hospital admission is planned for patients
with co-morbidity and/or insufficient postoperative supervision.
• The breast nurse informs the patient about the need for informal care in the home situation.
Table 2: Main indicators of the MaDO study.
Outcome indicators
• Final type of admission
• Readmission rate
• Complication rate
• Quality of care from the patients' perspective
• Cost-effectiveness of the ultra short stay programme
• Cost-effectiveness of the implementation strategy
Process indicators
• Involvement of home care nursing
• Performance of professionals according to the protocol
• Reasons why patients were not treated according to ultra short stay protocolBMC Cancer 2007, 7:117 http://www.biomedcentral.com/1471-2407/7/117
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groups fill out, through scoring by a researcher (MdK) of
all other costs (e.g. times, materials, travel costs) in a data
sheet. Effectiveness of the implementation strategy is
measured through Case Record Forms containing treat-
ment information. More details on programme cost-effec-
tiveness and policy cost-effectiveness can be found in the
section 'Economic evaluation'.
Time schedule for the study
The study lasts three years. The first year of the study will
be spent on the analysis of the breast cancer care processes
in the different hospitals and the development of the
measurement instruments. The following six months are
used for baseline measurements, and preparation of the
implementation of the new programme by the members
of the local study groups. Recruitment of patients will be
performed by breast nurses and advanced practice nurses
working at the breast units. Then, six months are used for
implementation and running of the actual programme,
followed by six months of measurements 'after imple-
mentation'.
Statistical analyses
Intention to treat will be used for data analyses, and anal-
yses will be performed using the SPSS package, version
12.0.1 ® for Windows (SPSS INC 1989–2003). P values <
0.05 will be defined as statistically significant. The pre and
post comparison of the interval scaled outcome variables
will be analysed with a multivariate linear regression
model. Apart from the independent variable hospital,
other independent variables included in this model are
type of surgery, age, informal care at home, involvement
of home care nursing and starting time of surgery. Further-
more, correlation of data within a hospital are accounted
for by clustered data analysis.
Economic evaluation
In the economic evaluation, programme cost-effective-
ness will be combined with cost-effectiveness of the
implementation strategy, to determine policy cost-effec-
tiveness.
Overview patient questionnaires Figure 1
Overview patient questionnaires. Overview of the type of questionnaires that are offered to patients and the time at 
which these questionnaires should be filled out.BMC Cancer 2007, 7:117 http://www.biomedcentral.com/1471-2407/7/117
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Programme cost-effectiveness
The time horizon of six weeks seems appropriate as
patients may receive additional treatment after surgery
(e.g. radiotherapy, chemotherapy or hormone replace-
ment therapy). Therefore, we expect that only short-term
quality-of-life effects and costs can be attributed to the
ultra short stay programme. Cost analysis includes health
care costs and costs outside health care such as out-of-
pocket costs or productivity costs due to reduction in paid
work and/or domestic activities. Health care costs refer to
hospital and other health care facilities costs. Hospital
costs consist of personnel, material, capacity costs, and
overhead, associated with the diagnosis, surgical treat-
ment, hospital stay and follow-up. Other healthcare costs
include costs of visits to the general practitioner, medica-
tion, home care etc. Health care costs are estimated by
multiplying the resource utilization with the cost price per
unit. Most of these costs are estimated by using existing
resource registration systems and available cost prices
through the financial departments of the participating
centres. If true cost prices are not available in the partici-
pating centres, 1) existing cost prices of the uhM or 2) offi-
cial directive prices are used[28]. Healthcare costs
incurred outside the hospital and costs outside health care
are partly estimated through a structured cost book that is
kept by all participating breast cancer patients during the
period of six weeks following discharge. Productivity
losses due to absence from work are estimated through
the friction cost method[28,29]. To perform the cost-
effectiveness analysis, costs and effects of patients treated
according to care as usual (before implementation) will
be compared to costs and effects of patients treated
according to the ultra short stay programme (after imple-
mentation).
Cost-effectiveness of implementation
In each centre, the costs of the implementation process are
calculated based on time and materials invested during
the different phases of implementation. The diagnostic
analysis may be looked upon as intervention. Its costs
should be included in the costs of implementation. To
determine cost-effectiveness of implementation, the costs
of implementation will be weighed against the proportion
of patients that is treated according to the ultra short stay
programme.
Policy cost-effectiveness
The cost-effectiveness of implementation, i.e. the extra
cost per patient treated according to the ultra short stay
programme, will be combined with the cost-effectiveness
of the breast cancer care programme to determine policy
cost-effectiveness, using Mason's model[9,30]. In this
model, the duration of the effects of implementation is
crucial for the cost-effectiveness of implementation,
which will be investigated explicitly in this study. The
incremental cost-effectiveness ratio of implementation of
the ultra short stay programme versus 'doing nothing' will
be expressed as the incremental cost per QALY.
Discussion
Breast cancer surgery on an inpatient basis is a burden on
the health care budget. Although previous studies have
shown that ambulatory surgery is feasible for breast can-
cer patients, this has not been widely recognised in
Europe. This is, to our knowledge, the first study that sys-
tematically evaluates the impact of an implementation
strategy on patient and professional outcomes, patient
experiences, costs, barriers and facilitators for change, for
ultra short stay after breast cancer surgery.
A randomised controlled trial is usually preferred over any
other design. However, for several reasons a randomised
controlled trial was not regarded as feasible. The first rea-
son concerns the expected lack of willingness on the part
of hospitals to be allocated to the control condition as
they would get nothing in return for their efforts had we
chosen a design with a concurrent control group. The
number of participating hospitals in the study is too small
to allow a controlled study design. A controlled study
would have led to an unacceptable rise in study costs and
the study period was too short to construct a waiting list
control group. However, we think that the numbers of
patients from the four participating hospitals provide
enough power to draw conclusions on the estimation of
change.
Random allocation at patient level was not considered for
legal and organisational reasons; patients always have the
right to go home whenever they want, making randomisa-
tion for early or late discharge rather meaningless. Moreo-
ver, it is unethical to have one patient discharged the day
of surgery while her neighbour is allowed to stay for
another day or two. The extent of organisational changes
to implement short stay within the existing processes of
care are of such a scale that it is hardly feasible nor accept-
able to allow different admission periods at the same time
within one hospital.
We are aware that the decision for a pre-post design
instead of a randomised controlled trial cannot rule out
the influence of developments and ongoing changes in
health care, including reductions in lengths of hospital
stays. This aspect will, therefore, be taken into account
when conclusions are drawn based on the results of the
study.
In line with the most recent insights in implementation
science a diagnostic analysis will be performed with the
intention to tailor the implementation strategies to the
needs of each hospital. However, this analysis will encom-BMC Cancer 2007, 7:117 http://www.biomedcentral.com/1471-2407/7/117
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pass a lot of time, energy, and costs, while there is no evi-
dence as yet that such an analysis will assure a positive
effect of implementation.
Since we wittingly selected merely early adopters, the
external validity may be limited with regard to the
smoothness of implementation. However, we think that
although not every hospital can be labelled an 'early
adopter', every hospital willing to participate in an imple-
mentation study must be eager to make the study a suc-
cess, regardless of the degree of novelty at that time.
Although diagnostic analysis explores the willingness to
implement as well as the opportunities for implementa-
tion, the number of perceived barriers and facilitators will
be underestimated, or at least not overestimated. A thor-
ough exploration of actual barriers and facilitators must,
therefore, be performed during the actual implementa-
tion process.
There is a risk of contamination of the baseline measure-
ment by socially desirable behaviour because the outreach
visits for preparation of the study have taken place before
and during the baseline measurement period. However,
fixed moments to actually start with the innovative pro-
gramme, are scheduled within each hospital and agreed
upon. Feedback is given by the researchers if they suspect
that hospitals may start the programme earlier than
planned. Therefore, we think this influence is limited.
A cost-effectiveness analysis is performed on the ultra
short stay programme itself, and on the implementation
strategy used. The goal of this study is to implement the
ultra short stay programme for breast cancer surgery aim-
ing at improved patient information, improved organiza-
tion of care, a high degree of quality of care, and a
reduction in mean hospital stay which results in a reduc-
tion of health care costs.
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